They are lofty numbers that underscore the potential impact of AI-116.

With access to a huge data library, including the biggest supercomputer in the Southern Hemisphere, Algorae is aiming to use the power of AI to transform the speed, cost and time to delivery of drug discovery and development. At a time when AI has made the headlines for its potentially negative impacts on humanity – with fears of job displacement, privacy concerns or a lack of creativity, ethics and emotion – Algorae is looking solely at the ways it can benefit the health and wellness of society.

Using its proprietary AI-enabled “AlgoraeOS” platform, the system is able to predict and prioritise drug targets by analysing biological data, identifying disease-associated pathways and predicting the likelihood of a target being viable for therapy. The new platform is able to fast-track the process of finding and approving new treatments to support targeted methods by using existing drugs and products that can be combined and used to treat a wider range of diseases.

Algorae’s latest laboratory findings clearly highlight the significant broad-spectrum neuroprotective potential of AI-116. With the important step now under its belt, the company looks set to ruffle a few more feathers in the scientific community as it puts the grunt of AI into the discovery of further improvements of legacy drug treatments.

Management says it is now seeking Australian experts in dementia studies to partner it towards a series of clinical in-human trials for AI-116.

Is your ASX-listed company doing something interesting? Contact: [email protected]